ContraFect Stock Price, News & Analysis (NASDAQ:CFRX)

$1.69 +0.04 (+2.42 %)
(As of 02/21/2018 02:01 PM ET)
Previous Close$1.69
Today's Range$1.65 - $1.83
52-Week Range$0.80 - $2.50
Volume228,600 shs
Average Volume219,009 shs
Market Capitalization$121.53 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.28

About ContraFect (NASDAQ:CFRX)

ContraFect logoContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Debt-to-Equity RatioN/A
Current Ratio18.43%
Quick Ratio18.43%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book3.60

Profitability

Trailing EPS($0.23)
Net Income$-28,530,000.00
Net MarginsN/A
Return on Equity-84.07%
Return on Assets-44.69%

Miscellaneous

Employees23
Outstanding Shares73,660,000

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) announced its quarterly earnings data on Wednesday, August, 9th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.11. View ContraFect's Earnings History.

When will ContraFect make its next earnings announcement?

ContraFect is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for ContraFect.

Who are some of ContraFect's key competitors?

Who owns ContraFect stock?

ContraFect's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (1.67%), Anson Funds Management LP (0.40%), Renaissance Technologies LLC (0.26%), White Pine Capital LLC (0.26%) and Deutsche Bank AG (0.16%). Company insiders that own ContraFect stock include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Institutional Ownership Trends for ContraFect.

Who sold ContraFect stock? Who is selling ContraFect stock?

ContraFect's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC and White Pine Capital LLC. View Insider Buying and Selling for ContraFect.

Who bought ContraFect stock? Who is buying ContraFect stock?

ContraFect's stock was bought by a variety of institutional investors in the last quarter, including Anson Funds Management LP, Renaissance Technologies LLC and Deutsche Bank AG. Company insiders that have bought ContraFect stock in the last two years include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Insider Buying and Selling for ContraFect.

How do I buy ContraFect stock?

Shares of ContraFect can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of ContraFect stock can currently be purchased for approximately $1.69.

How big of a company is ContraFect?

ContraFect has a market capitalization of $121.53 million. The biotechnology company earns $-28,530,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. ContraFect employs 23 workers across the globe.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]


MarketBeat Community Rating for ContraFect (CFRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ContraFect (NASDAQ:CFRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.002.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$5.00
Price Target Upside: N/AN/AN/A284.62% upside

ContraFect (NASDAQ:CFRX) Consensus Price Target History

Price Target History for ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ:CFRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Maxim GroupReiterated RatingHoldLowView Rating Details
11/21/2016Piper Jaffray CompaniesSet Price TargetBuy$5.00N/AView Rating Details
9/28/2016William BlairInitiated CoverageOutperformN/AView Rating Details
5/10/2016Roth CapitalDowngradeBuy -> Neutral$4.00 -> $3.30N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

ContraFect (NASDAQ:CFRX) Earnings History and Estimates Chart

Earnings by Quarter for ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ CFRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/9/2017Q3 2017($0.11)$0.04ViewN/AView Earnings Details
8/9/2017Q2 2017($0.18)($0.07)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.17)($0.15)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.20)$0.01ViewN/AView Earnings Details
11/9/2016Q3 2016($0.21)($0.28)ViewN/AView Earnings Details
8/9/2016Q216($0.27)($0.35)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.32)ViewN/AView Earnings Details
3/15/2016Q415($0.23)($0.28)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.29)($0.22)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.27)($0.33)ViewN/AView Earnings Details
5/15/2015Q1 2015($0.26)($0.24)ViewN/AView Earnings Details
4/6/2015Q4 2014($0.23)($0.23)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.13)($1.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ContraFect (NASDAQ:CFRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS

Dividends

Dividend History for ContraFect (NASDAQ:CFRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ContraFect (NASDAQ CFRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 60.38%
Insider Trades by Quarter for ContraFect (NASDAQ:CFRX)
Institutional Ownership by Quarter for ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ CFRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2017Cara M CassinoInsiderBuy8,000$1.24$9,920.008,000View SEC Filing  
7/25/2017Joshua B MuntnerSVPBuy2,000$1.24$2,480.002,000View SEC Filing  
7/25/2017Sol J BarerDirectorBuy40,000$1.24$49,600.00815,933View SEC Filing  
7/25/2017Steven C GilmanCEOBuy800$1.24$992.0020,800View SEC Filing  
7/27/2016Steven C GilmanCEOBuy20,000$2.48$49,600.0020,000View SEC Filing  
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32View SEC Filing  
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.412,872View SEC Filing  
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.165,739View SEC Filing  
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.378,606View SEC Filing  
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.9210,773View SEC Filing  
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.3014,340View SEC Filing  
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ContraFect (NASDAQ CFRX) News Headlines

Source:
DateHeadline
Head to Head Comparison: ContraFect (CFRX) & SIGA Technologies (SIGA)Head to Head Comparison: ContraFect (CFRX) & SIGA Technologies (SIGA)
www.americanbankingnews.com - February 20 at 1:06 AM
Comparing VBI Vaccines (VBIV) & ContraFect (CFRX)Comparing VBI Vaccines (VBIV) & ContraFect (CFRX)
www.americanbankingnews.com - February 15 at 12:46 PM
-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter
www.americanbankingnews.com - February 13 at 5:24 AM
Zacks: Analysts Expect ContraFect Corp (CFRX) Will Post Earnings of -$0.10 Per ShareZacks: Analysts Expect ContraFect Corp (CFRX) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - January 27 at 5:16 AM
Analyzing XOMA (XOMA) and ContraFect (CFRX)Analyzing XOMA (XOMA) and ContraFect (CFRX)
www.americanbankingnews.com - January 21 at 7:16 AM
ContraFect to Present at Cantor Antibiotics SummitContraFect to Present at Cantor Antibiotics Summit
finance.yahoo.com - January 11 at 10:20 AM
Head to Head Comparison: ContraFect (CFRX) & Mateon Therapeutics (MATN)Head to Head Comparison: ContraFect (CFRX) & Mateon Therapeutics (MATN)
www.americanbankingnews.com - January 7 at 9:40 PM
ContraFect to Present at 10th Annual Biotech ShowcaseContraFect to Present at 10th Annual Biotech Showcase
finance.yahoo.com - January 3 at 9:20 AM
 Brokerages Set $5.00 Target Price for ContraFect Corp (CFRX) Brokerages Set $5.00 Target Price for ContraFect Corp (CFRX)
www.americanbankingnews.com - December 30 at 1:46 PM
Comparing ContraFect (CFRX) & Mirati Therapeutics (MRTX)Comparing ContraFect (CFRX) & Mirati Therapeutics (MRTX)
www.americanbankingnews.com - December 28 at 3:02 PM
ContraFect (CFRX) vs. Soligenix (SNGX) Financial ComparisonContraFect (CFRX) vs. Soligenix (SNGX) Financial Comparison
www.americanbankingnews.com - December 24 at 9:33 PM
-$0.10 EPS Expected for ContraFect Corp (CFRX) This Quarter-$0.10 EPS Expected for ContraFect Corp (CFRX) This Quarter
www.americanbankingnews.com - December 24 at 5:32 PM
 Analysts Set $5.00 Price Target for ContraFect Corp (CFRX) Analysts Set $5.00 Price Target for ContraFect Corp (CFRX)
www.americanbankingnews.com - December 16 at 4:48 AM
Contrasting Jazz Pharmaceuticals (JAZZ) & ContraFect (CFRX)Contrasting Jazz Pharmaceuticals (JAZZ) & ContraFect (CFRX)
www.americanbankingnews.com - December 9 at 1:22 AM
 Brokerages Expect ContraFect Corporation (CFRX) Will Post Earnings of -$0.10 Per Share Brokerages Expect ContraFect Corporation (CFRX) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 7 at 1:20 AM
Zacks: Brokerages Set $5.00 Target Price for ContraFect Corporation (CFRX)Zacks: Brokerages Set $5.00 Target Price for ContraFect Corporation (CFRX)
www.americanbankingnews.com - November 30 at 2:18 PM
ContraFect Corporation (CFRX) Expected to Post FY2017 Earnings of ($0.33) Per ShareContraFect Corporation (CFRX) Expected to Post FY2017 Earnings of ($0.33) Per Share
www.americanbankingnews.com - November 30 at 7:32 AM
CFRX: Additional Data on CF-301 Presented at ID Week 2017CFRX: Additional Data on CF-301 Presented at ID Week 2017
finance.yahoo.com - November 27 at 6:19 PM
ContraFect (CFRX) and Windtree Therapeutics (WINT) Critical AnalysisContraFect (CFRX) and Windtree Therapeutics (WINT) Critical Analysis
www.americanbankingnews.com - November 25 at 7:12 PM
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare ConferenceContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 16 at 12:39 PM
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA ConferenceContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
finance.yahoo.com - November 10 at 10:08 AM
ContraFect Announces Third Quarter 2017 Financial ResultsContraFect Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 7:58 PM
ContraFect reports 3Q lossContraFect reports 3Q loss
finance.yahoo.com - November 9 at 7:58 PM
Financial Analysis: ContraFect Corporation (CFRX) and Oncolytics Biotech, Inc. (USA) (ONCY)Financial Analysis: ContraFect Corporation (CFRX) and Oncolytics Biotech, Inc. (USA) (ONCY)
www.americanbankingnews.com - November 9 at 7:58 AM
Critical Comparison: ContraFect Corporation (CFRX) vs. Dendreon (DNDN)Critical Comparison: ContraFect Corporation (CFRX) vs. Dendreon (DNDN)
www.americanbankingnews.com - November 8 at 3:58 PM
Who Are The Major Shareholders Of ContraFect Corporation (CFRX)?Who Are The Major Shareholders Of ContraFect Corporation (CFRX)?
finance.yahoo.com - November 7 at 8:05 PM
ContraFect Corporation (CFRX) to Release Quarterly Earnings on TuesdayContraFect Corporation (CFRX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
ContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development SummitContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit
finance.yahoo.com - October 17 at 5:53 PM
ContraFect Appoints Lisa Ricciardi as Chief Operating OfficerContraFect Appoints Lisa Ricciardi as Chief Operating Officer
feeds.benzinga.com - October 5 at 7:53 AM
ContraFect Corporation (CFRX) vs. The Competition Critical AnalysisContraFect Corporation (CFRX) vs. The Competition Critical Analysis
www.americanbankingnews.com - September 29 at 2:36 PM
ContraFect to Present at The MicroCap Conference - GlobeNewswire (press release)ContraFect to Present at The MicroCap Conference - GlobeNewswire (press release)
globenewswire.com - September 29 at 2:11 PM
ContraFect to Present at The MicroCap ConferenceContraFect to Present at The MicroCap Conference
www.nasdaq.com - September 28 at 6:23 PM
Critical Comparison: ContraFect Corporation (CFRX) versus Its PeersCritical Comparison: ContraFect Corporation (CFRX) versus Its Peers
www.americanbankingnews.com - September 27 at 4:32 PM
Analyzing ContraFect Corporation (CFRX) and Its CompetitorsAnalyzing ContraFect Corporation (CFRX) and Its Competitors
www.americanbankingnews.com - September 23 at 10:20 AM
Analyzing ContraFect Corporation (CFRX) and The CompetitionAnalyzing ContraFect Corporation (CFRX) and The Competition
www.americanbankingnews.com - September 17 at 10:16 AM
ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare ConferenceContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 13 at 6:19 PM
ContraFect to Present at 2017 World Antimicrobial Resistance CongressContraFect to Present at 2017 World Antimicrobial Resistance Congress
finance.yahoo.com - September 11 at 5:46 PM
Contrasting ContraFect Corporation (CFRX) & its RivalsContrasting ContraFect Corporation (CFRX) & its Rivals
www.americanbankingnews.com - September 10 at 8:38 AM
Contrasting ContraFect Corporation (CFRX) and Tetralogic Pharmaceuticals Corp (TLOG)Contrasting ContraFect Corporation (CFRX) and Tetralogic Pharmaceuticals Corp (TLOG)
www.americanbankingnews.com - September 4 at 2:12 AM
ContraFect Corporation Forecasted to Post Q3 2017 Earnings of ($0.11) Per Share (CFRX)ContraFect Corporation Forecasted to Post Q3 2017 Earnings of ($0.11) Per Share (CFRX)
www.americanbankingnews.com - August 16 at 7:22 AM
-$0.14 EPS Expected for ContraFect Corporation (CFRX) This Quarter-$0.14 EPS Expected for ContraFect Corporation (CFRX) This Quarter
www.americanbankingnews.com - August 15 at 6:06 PM
CFRX: Sufficient Capital To Fund Company Past Phase 2 Results for CF-301CFRX: Sufficient Capital To Fund Company Past Phase 2 Results for CF-301
finance.yahoo.com - August 14 at 5:29 PM
Equities Analysts Set Expectations for ContraFect Corporations Q3 2017 Earnings (NASDAQ:CFRX)Equities Analysts Set Expectations for ContraFect Corporation's Q3 2017 Earnings (NASDAQ:CFRX)
www.americanbankingnews.com - August 11 at 9:48 AM
ContraFect Corporation (CFRX) Issues  Earnings Results, Beats Expectations By $0.11 EPSContraFect Corporation (CFRX) Issues Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - August 10 at 8:02 PM
ContraFect Announces Second Quarter 2017 Financial ResultsContraFect Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:17 PM
ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled AntibodiesContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies
finance.yahoo.com - August 3 at 6:37 PM
ContraFect Corporation (CFRX) Expected to Announce Earnings of -$0.16 Per ShareContraFect Corporation (CFRX) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 28 at 2:30 PM
CFRX: New Clinical and Microbiological Data Presented on CF-301; New Financing To Fund Company Past Phase 2 Results for CF-301CFRX: New Clinical and Microbiological Data Presented on CF-301; New Financing To Fund Company Past Phase 2 Results for CF-301
finance.yahoo.com - July 27 at 4:33 PM
Insider Buying: ContraFect Corporation (NASDAQ:CFRX) Director Buys 40,000 Shares of StockInsider Buying: ContraFect Corporation (NASDAQ:CFRX) Director Buys 40,000 Shares of Stock
www.americanbankingnews.com - July 26 at 8:48 PM
ContraFect Corporation Prices $40 Million Public Offering of Common Stock and WarrantsContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants
finance.yahoo.com - July 20 at 6:52 PM

SEC Filings

ContraFect (NASDAQ:CFRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ContraFect (NASDAQ:CFRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ContraFect (NASDAQ CFRX) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.